Cargando…

The gamma-glutamyl transferase to platelet ratio for noninvasive evaluation of liver fibrosis in patients with primary biliary cholangitis

The gamma-glutamyl transferase to platelet ratio (GPR) has been reported to be as effective as the aspartate transaminase to platelet ratio index (APRI) and fibrosis index based on the 4 factors (FIB-4) in showing the fibrosis stage in patients with chronic hepatitis B. It has been demonstrated that...

Descripción completa

Detalles Bibliográficos
Autores principales: Avcioğlu, Ufuk, Eruzun, Hasan, Ustaoğlu, Müge
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9542841/
https://www.ncbi.nlm.nih.gov/pubmed/36221370
http://dx.doi.org/10.1097/MD.0000000000030626
_version_ 1784804241716543488
author Avcioğlu, Ufuk
Eruzun, Hasan
Ustaoğlu, Müge
author_facet Avcioğlu, Ufuk
Eruzun, Hasan
Ustaoğlu, Müge
author_sort Avcioğlu, Ufuk
collection PubMed
description The gamma-glutamyl transferase to platelet ratio (GPR) has been reported to be as effective as the aspartate transaminase to platelet ratio index (APRI) and fibrosis index based on the 4 factors (FIB-4) in showing the fibrosis stage in patients with chronic hepatitis B. It has been demonstrated that APRI and FIB-4 are successful in the assessment of fibrosis in primary biliary cholangitis (PBC). We investigated the effectiveness of GPR in predicting advanced fibrosis and cirrhosis in patients with biopsy-proven untreated PBC. A total of 35 patients with biopsy-proven PBC were included in this study. The biopsy fibrosis stages of all patients at diagnosis were compared using the APRI, FIB-4, and GPR values. The diagnostic accuracy of GPR for detecting advanced fibrosis and cirrhosis was also investigated. The area under the receiver operating characteristic curve (AUROC) of GPR was 0.84, the cutoff point was 4.81, the sensitivity was 0.41, and the specificity was 0.96 for detecting advanced fibrosis. Our study showed that GPR was more sensitive than APRI and FIB-4 in detecting advanced fibrosis in patients with PBC. GPR could be used as an effective noninvasive marker in PBC to show advanced fibrosis at the time of diagnosis.
format Online
Article
Text
id pubmed-9542841
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-95428412022-10-11 The gamma-glutamyl transferase to platelet ratio for noninvasive evaluation of liver fibrosis in patients with primary biliary cholangitis Avcioğlu, Ufuk Eruzun, Hasan Ustaoğlu, Müge Medicine (Baltimore) Research Article The gamma-glutamyl transferase to platelet ratio (GPR) has been reported to be as effective as the aspartate transaminase to platelet ratio index (APRI) and fibrosis index based on the 4 factors (FIB-4) in showing the fibrosis stage in patients with chronic hepatitis B. It has been demonstrated that APRI and FIB-4 are successful in the assessment of fibrosis in primary biliary cholangitis (PBC). We investigated the effectiveness of GPR in predicting advanced fibrosis and cirrhosis in patients with biopsy-proven untreated PBC. A total of 35 patients with biopsy-proven PBC were included in this study. The biopsy fibrosis stages of all patients at diagnosis were compared using the APRI, FIB-4, and GPR values. The diagnostic accuracy of GPR for detecting advanced fibrosis and cirrhosis was also investigated. The area under the receiver operating characteristic curve (AUROC) of GPR was 0.84, the cutoff point was 4.81, the sensitivity was 0.41, and the specificity was 0.96 for detecting advanced fibrosis. Our study showed that GPR was more sensitive than APRI and FIB-4 in detecting advanced fibrosis in patients with PBC. GPR could be used as an effective noninvasive marker in PBC to show advanced fibrosis at the time of diagnosis. Lippincott Williams & Wilkins 2022-10-07 /pmc/articles/PMC9542841/ /pubmed/36221370 http://dx.doi.org/10.1097/MD.0000000000030626 Text en Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC) (https://creativecommons.org/licenses/by-nc/4.0/) , where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal.
spellingShingle Research Article
Avcioğlu, Ufuk
Eruzun, Hasan
Ustaoğlu, Müge
The gamma-glutamyl transferase to platelet ratio for noninvasive evaluation of liver fibrosis in patients with primary biliary cholangitis
title The gamma-glutamyl transferase to platelet ratio for noninvasive evaluation of liver fibrosis in patients with primary biliary cholangitis
title_full The gamma-glutamyl transferase to platelet ratio for noninvasive evaluation of liver fibrosis in patients with primary biliary cholangitis
title_fullStr The gamma-glutamyl transferase to platelet ratio for noninvasive evaluation of liver fibrosis in patients with primary biliary cholangitis
title_full_unstemmed The gamma-glutamyl transferase to platelet ratio for noninvasive evaluation of liver fibrosis in patients with primary biliary cholangitis
title_short The gamma-glutamyl transferase to platelet ratio for noninvasive evaluation of liver fibrosis in patients with primary biliary cholangitis
title_sort gamma-glutamyl transferase to platelet ratio for noninvasive evaluation of liver fibrosis in patients with primary biliary cholangitis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9542841/
https://www.ncbi.nlm.nih.gov/pubmed/36221370
http://dx.doi.org/10.1097/MD.0000000000030626
work_keys_str_mv AT avciogluufuk thegammaglutamyltransferasetoplateletratiofornoninvasiveevaluationofliverfibrosisinpatientswithprimarybiliarycholangitis
AT eruzunhasan thegammaglutamyltransferasetoplateletratiofornoninvasiveevaluationofliverfibrosisinpatientswithprimarybiliarycholangitis
AT ustaoglumuge thegammaglutamyltransferasetoplateletratiofornoninvasiveevaluationofliverfibrosisinpatientswithprimarybiliarycholangitis
AT avciogluufuk gammaglutamyltransferasetoplateletratiofornoninvasiveevaluationofliverfibrosisinpatientswithprimarybiliarycholangitis
AT eruzunhasan gammaglutamyltransferasetoplateletratiofornoninvasiveevaluationofliverfibrosisinpatientswithprimarybiliarycholangitis
AT ustaoglumuge gammaglutamyltransferasetoplateletratiofornoninvasiveevaluationofliverfibrosisinpatientswithprimarybiliarycholangitis